Wilbanks Smith & Thomas Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-23,641	Closed	-$407K	–	496
2023 Q2	$407K	Sell	23,641 -1,496	-6%	-$22.5K	0.01%	358
2023 Q1	$417K	Hold	25,137	–	–	0.01%	340
2022 Q4	$192K	Hold	25,137	–	–	0.01%	480
2022 Q3	$250K	Buy	25,137 +41	+0.2%	+$426	0.01%	402
2022 Q2	$228K	Hold	25,096	–	–	0.01%	431
2022 Q1	$209K	Buy	+25,096	New	+$258K	0.01%	472
2021 Q4	–	Sell	-5,702	Closed	-$267K	–	511
2021 Q3	$267K	Buy	+5,702	New	+$306K	0.01%	420

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's BBIO Position: Q3 2023 in Review

Wilbanks Smith & Thomas Asset Management sold out of BridgeBio Pharma (BBIO) in Q3 2023, closing a stake of 23,641 shares — an estimated $407K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in BBIO in Q3 2021 and held it in 7 quarters. The position peaked at $417K in Q1 2023. 221 funds tracked by Wall St. Rank hold BBIO as of Q3 2023.

Wilbanks Smith & Thomas Asset Management reported no remaining BridgeBio Pharma position as of Q3 2023 after selling out during the quarter.
Wilbanks Smith & Thomas Asset Management sold 23,641 BridgeBio Pharma shares in Q3 2023, an estimated $407K.
Wilbanks Smith & Thomas Asset Management first reported a position in BridgeBio Pharma in Q3 2021 and held it in 7 quarters.
Wilbanks Smith & Thomas Asset Management's BridgeBio Pharma position peaked at $417K in Q1 2023.
221 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2023.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q3 2023, filed 6 Nov 2023.